Ann: Quarterly Activity Report & Appendix 4C, page-44

I thought EMD AML was one of the many shots on goal for potential progression. I am not sure old formula Zantrene with orphan drug designation is the approval pathway desired if new formulation Zantrene resets the IP clock with longer and better commercials and duration than ODD. That is, they would progress all options and then persue the most commercially advantageous if all shots looked good. EMD AML with old formula (central line) could still provide good data for BP in the meantime on FTO and cardio. With the delay in this trial I would question if just going with new formulation would not be better to wait but there now may be a question mark on timing over new formulation or requirements for safety and toxicity that are not grandfathered through old formulations.